Human Xt-M (HUMX.M) AI Stock Analysis

• Market Cap: 4.92M
• Dividend Yield: N/A
• Average Volume (3M): 50.09K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.06
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: IL
• Employees: 21
• Sector: Technology
• Sector Strength: 88
• Industry: Medical - Devices
• EPS (TTM): N/A
• Shares Outstanding: 26,756,048
• 10 Day Avg. Volume: 22,744
• 30 Day Avg. Volume: 50,094
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: 18.00 ▼(-30.23% Downside)

The score is weighed down primarily by deteriorating financial performance (sharp 2024 revenue decline, worsening losses, and ongoing cash burn with shrinking equity). Technicals also contribute negatively with the price below all key moving averages and weak momentum (negative MACD and very low RSI). Valuation is only modestly supportive because the negative P/E reflects unprofitability and there is no dividend yield data to provide offsetting support.

Positive Factors

Low leverage / zero reported debt

Zero reported debt materially reduces interest and refinancing pressure, giving the company structural financial flexibility. Over a multi‑month horizon this lowers bankruptcy risk and makes external funding or restructuring less urgent, supporting operational continuity.

Improving cash burn versus worst years

Evidence of reduced cash burn versus peak years indicates management has begun to rein in outflows or operate more efficiently. If sustained, this structural improvement lengthens runway and increases the chance that the firm can reach break‑even without immediate dilutive financing.

Historic revenue growth in 2022–2023

Prior multi‑year revenue growth demonstrates the business has delivered demand and commercial traction historically. This suggests underlying product or market fit that could support a recovery if execution stabilizes and structural issues driving the 2024 decline are addressed.

Negative Factors

Sharp 2024 revenue collapse

A ~74% YoY revenue decline is a structural red flag: it erodes operating leverage, undermines fixed‑cost coverage, and signals either lost customer demand or contract rolloffs. Sustained top‑line deterioration makes margin recovery and cash generation much harder without strategic change.

Negative gross profit and widening losses

Negative gross profit means product costs exceed revenue, a severe structural profitability issue. Widening operating and net losses indicate current business economics are unsustainable long term; fixing this requires durable cost base reductions or meaningful, sustained revenue recovery.

Persistent cash burn and shrinking equity

Chronic negative operating and free cash flow combined with dramatic equity erosion point to sustained funding needs and capital base depletion. Over months this raises financing and dilution risk, constrains strategic options, and threatens long‑term solvency absent structural operational improvement.

Human Xt-M Business Overview & Revenue Model

Company Description

Human Xtensions Ltd. develops, manufactures, markets and sells a modular medical device for minimally invasive surgical operations. It offers HandX, a handheld electromechanical device for use in laparoscopic procedures; Fenestrated Grasper; Monopolar Hook; and Needle Holder. The company was incorporated in 2012 and is based in Netanya, Israel.

How the Company Makes Money

Human Xt (HUMX) generates revenue through the sale of its smart wearable devices and augmented reality applications, which are available to both individual consumers and corporate clients. The company also offers AI-driven software solutions on a subscription basis, providing continuous updates and support. Key revenue streams include direct product sales, subscription fees for software services, and partnerships with technology firms to integrate HUMX's solutions into broader ecosystems. Additionally, strategic alliances with enterprise clients in various industries allow the company to create customized solutions that cater to specific business needs, thereby enhancing its earnings.

Human Xt-M Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Human Xt-M Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 25.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:HUMX.M, the sentiment is Negative. The current price of 25.8 is above the 20-day moving average (MA) of 16.60, above the 50-day MA of 19.99, and below the 200-day MA of 27.36, indicating a neutral trend. The MACD of -0.63 indicates Negative momentum. The RSI at 54.16 is Neutral, neither overbought nor oversold. The STOCH value of 92.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:HUMX.M.

Human Xt-M Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	61 Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%
HUMX.M	44 Neutral	4.92M	-0.53	―	―	―	―